About Prostatype Genomics

Prostatype Genomics AB is a company specialized in the development, manufacturing, and marketing of the prognostic genetic test Prostatype. Prostatype is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.

Over-treatment of prostate cancer, which can lead to lifelong side effects, is a well-known problem in Sweden and in the Western world. At the same time, it is important to identify patients who have an aggressive form of cancer in order to offer the right treatment. Prostatype helps doctors and patients make correct treatment decisions for individuals with prostate cancer. By minimizing over- and under-treatment, the quality of life for patients can be improved and resources can be saved within healthcare.

Prostatype Genomics is a publicly traded company listed on the Nasdaq First North Growth Market in Stockholm since 2020. The company has offices in Solna, Sweden, Valencia, Spain, and Denver, Colorado, USA. The manufacturing of Prostatype takes place in Berlin, Germany.

Prostatype has been a CE-marked product since 2016 and has been commercialized in selected markets in Europe since 2022. Prostatype Genomics is certified according to ISO 13485. The company has its own research laboratory in close collaboration with the Karolinska University Hospital in Stockholm. The company’s headquarters are located in Solna.

Prostatype Genomics conducts active research and development in the field of prostate cancer and continuously invests in studies and product development. The company has conducted a large number of studies to develop and validate Prostatype’s accuracy when used for patients diagnosed with prostate cancer, especially for patients with low or intermediate risk, which constitute the majority of all newly diagnosed cases. These studies have been conducted at hospitals in Sweden, Spain, Germany, Taiwan, China, and the USA. In total, approximately 2500 patients have participated in clinical studies with Prostatype so far. Currently, the company is involved in several studies in Sweden, Spain, and the USA.

The USA is the world’s largest market for prognostic biomarkers in prostate cancer. Approximately 300,000 patients are diagnosed annually in the USA, making the addressable annual market estimate around 6 billion SEK in the USA alone. In Sweden, approximately 12,000 patients are diagnosed with prostate cancer annually.

Our history

Prostatype Genomics is based on research conducted at the Karolinska Institutet in Stockholm. Founded in 2007, Prostatype Genomics was established to further develop the method and create a product with associated software that, using an RNA-based gene panel, can compare your genes to a comprehensive patient database consisting of patients diagnosed with prostate cancer. Over 15 years of research and development have resulted in the development of a new type of gene analysis.

The result is Prostatype. The test provides more accurate prognostication of your cancer, increases understanding of your risk profile, and creates better opportunities for you to receive appropriate care.

Prostatype is based on a gene expression test that measures the expression of three carefully selected embryonic stem cell genes in biopsies from prostate cancer. By combining these genetic data with clinical parameters such as PSA, Gleason score, and tumor stage, Prostatype can predict overall survival in prostate cancer. This allows for a more precise selection of patients who may benefit from radical treatment, such as surgery or radiation, and patients who do not need to undergo such procedures and can then maintain their quality of life.

We are proud to have developed a product that can help avoid overtreatment and provide patients with a more individualized and tailored treatment. Our goal is to improve the prognosis for patients with prostate cancer and contribute to increasing the quality of life for those affected by this disease. We continue to conduct research and development to improve and expand the use of the Prostatype Gene Test and make it available to as many patients as possible.

Our vision and mission

Our vision is for doctors and patients facing a diagnosis of prostate cancer to have full confidence in their treatment decisions.

Prostatype Genomics’ mission is to make a difference in the lives of prostate cancer patients by discovering and commercializing genetic tests to guide treatment decisions. In doing so, we can increase the quality of life and peace of mind for patients while simultaneously reducing healthcare costs. Prostatype Genomics will achieve this by making Prostatype the global first-choice test system for patients with newly diagnosed prostate cancer or those on active surveillance.